Document and Entity Information - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2021

Feb. 25, 2022

Jun. 30, 2021

Cover [Abstract]

Document Type

10-K

Document Annual Report

true

Document Transition Report

false

Document Period End Date

Dec. 31, 2021

Document Fiscal Year Focus

2021

Document Fiscal Period Focus

FY

Current Fiscal Year End Date

--12-31

Entity File Number

1-36282

Entity Registrant Name

LA JOLLA PHARMACEUTICAL COMPANY

Entity Incorporation, State or Country Code

DE

Entity Tax Identification Number

33-0361285

Entity Address, Address Line One

201 Jones Road

Entity Address, Address Line Two

Suite 400

Entity Address, City or Town

Waltham

Entity Address, State or Province

MA

Entity Address, Postal Zip Code

02451

City Area Code

617

Local Phone Number

715-3600

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

LJPC

Security Exchange Name

NASDAQ

Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Filer Category

Non-accelerated Filer

Entity Small Business

true

Entity Emerging Growth Company

false

Shell Company

false

Entity Common Stock, Shares Outstanding

25,961,836

Entity Central Index Key

0000920465

Amendment Flag

false

Entity Public Float

$ 73.3

Entity Well-known Seasoned Issuer

No

Entity Voluntary Filers

No

ICFR Auditor Attestation Flag

false

Auditor Firm ID

23

Auditor Name

BAKER TILLY US, LLP

Auditor Location

San Diego, California

Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.